A Phase 3 interventional study of Tadalafil and Placebo in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 31 sites in 2 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2010-09-14.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 12th largest by enrollment, is one of 5 that started in 2009, is one of 10 in phase 3, and was the 7th registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Assiut University
Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 45 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 6
First in 2004; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 318 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 258 across the 26 interventional studies. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 26 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
17 studies in Prostatic Hyperplasia by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 17 finished, 16 (94%) have results posted.
Among the 17 studies in Prostatic Hyperplasia by Eli Lilly and Company, this one is the 11th largest by enrollment, is one of 5 that started in 2009, is one of 9 in phase 3, and was the 7th registered.
Eli Lilly and Company’s Prostatic Hyperplasia studies by the year they started, since 2004.
1 of the studies testing tadalafil in Prostatic Hyperplasia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654413Beni-Suef UniversityTamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 17 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of tadalafil when given to men who are currently taking a medication called an alpha blocker for the treatment of benign prostatic hyperplasia (BPH) symptoms (such as urinary frequency, urgency, and a feeling that the bladder is not completely emptied after urination).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have not taken the following treatments within the indicated duration and agree not to use at any time during the study:
Exclusion Criteria:
Drug: Placebo
Drug: Tadalafil
5 mg taken by mouth once daily for 12 weeks
Also known as: LY450190, Cialis
By mouth once daily for 12 weeks
Number of Men With Treatment-emergent Dizziness
The primary safety measure is the proportion (reported in numbers) of subjects experiencing treatment-emergent dizziness to include the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms of dizziness, dizziness postural, and procedural dizziness. Treatment-emergent dizziness is defined as any of the predefined terms of dizziness that is first reported or worsens in severity after baseline.
Time frame: Baseline through 12 Weeks
Number of Participants With Positive Orthostatic Vital Signs Test; Shift From Any Pre-Randomization to Any Post-Randomization Visit
A positive orthostatic test is defined as at least one of the following 4 criteria being met at any pre-randomization or post-randomization visit: (1) reduction in systolic blood pressure of \>= 20 mmHg from the supine to standing position;(2)reduction in diastolic blood pressure of \>=10 mmHg from the supine to standing position;(3)increase in heart rate of \>= 20 bpm from the supine to standing position; or (4)Unable to remain standing. A negative orthostatic test is defined as none of the above 4 criteria (1, 2, 3, or 4) being met at any pre-randomization or post-randomization visit.
Time frame: Baseline through 12 Weeks
International Prostate Symptom Score (IPSS) Change From Baseline
Change from baseline to endpoint in IPSS Score. The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
Time frame: Baseline, 12 Weeks
Postvoid Residual Volume (PVR) Change From Baseline
Change from baseline to endpoint in PVR volume. PVR is obtained by measuring with ultrasound the remaining urine in the bladder after urination.
Time frame: Baseline, 12 Weeks
Uroflowmetry (Qmax) Change From Baseline
Change from baseline to endpoint in Qmax. Qmax is defined as the peak urine flow rate (measured in milliliters per second \[mL/second\] using standard calibrated flowmeter).
Time frame: Baseline, 12 Weeks
| Milestone | Placebo | Tadalafil |
|---|---|---|
| Started | 160 | 158 |
| Completed | 140 | 140 |
| Not completed | 20 | 18 |
| Withdrew: Adverse event | 6 | 7 |
| Withdrew: Protocol violation | 8 | 5 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Physician decision | 0 | 3 |
| Withdrew: Withdrawal by subject | 5 | 3 |
The primary safety measure is the proportion (reported in numbers) of subjects experiencing treatment-emergent dizziness to include the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms of dizziness, dizziness postural, and procedural dizziness. Treatment-emergent dizziness is defined as any of the predefined terms of dizziness that is first reported or worsens in severity after baseline.
| Participants | Placebo | Tadalafil |
|---|---|---|
| Number of Men With Treatment-emergent Dizziness | 9 | 11 |
A positive orthostatic test is defined as at least one of the following 4 criteria being met at any pre-randomization or post-randomization visit: (1) reduction in systolic blood pressure of \>= 20 mmHg from the supine to standing position;(2)reduction in diastolic blood pressure of \>=10 mmHg from the supine to standing position;(3)increase in heart rate of \>= 20 bpm from the supine to standing position; or (4)Unable to remain standing. A negative orthostatic test is defined as none of the above 4 criteria (1, 2, 3, or 4) being met at any pre-randomization or post-randomization visit.
| Participants | Placebo | Tadalafil |
|---|---|---|
| Positive Pre-Random. to Negative Post-Random. | 22 | 15 |
| Negative Pre-Random. to Positive Post-Random. | 21 | 19 |
| Positive Pre-Random. to Positive Post-Random. | 14 | 16 |
| Negative Pre-Random. to Negative Post-Random. | 101 | 106 |
Change from baseline to endpoint in IPSS Score. The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
| units on a scale | Placebo | Tadalafil |
|---|---|---|
| Baseline | 13.3 ± 6.57 | 13.87 ± 7.15 |
| Change from Baseline | -1.49 ± 5.29 | -2.28 ± 5.65 |
Change from baseline to endpoint in PVR volume. PVR is obtained by measuring with ultrasound the remaining urine in the bladder after urination.
| milliliters | Placebo | Tadalafil |
|---|---|---|
| Baseline values | 70.7 ± 74.87 | 80.3 ± 80.78 |
| Change from Baseline | -1.9 ± 82.86 | -8.1 ± 88.5 |
Change from baseline to endpoint in Qmax. Qmax is defined as the peak urine flow rate (measured in milliliters per second \[mL/second\] using standard calibrated flowmeter).
| milliliters per second | Placebo | Tadalafil |
|---|---|---|
| Baseline | 12.8 ± 5.88 | 11.8 ± 4.93 |
| Change from Baseline | 0.6 ± 4.03 | 0.6 ± 3.67 |
Collected over Treatment Emergent Adverse Events were collected from randomization until the subject completed the study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 3/160 (1.9%) | 53/160 (33.1%) |
| Tadalafil | — | 2/158 (1.3%) | 65/158 (41.1%) |
| Event | Placebo | Tadalafil |
|---|---|---|
| Mallory-Weiss syndromeGastrointestinal disorders | 0/160 | 1/158 |
| FallInjury, poisoning and procedural complications | 1/160 | 1/158 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/160 | 1/158 |
| Non-cardiac chest painGeneral disorders | 1/160 | 0/158 |
| Hip fractureInjury, poisoning and procedural complications | 1/160 | 0/158 |
| Lead dislodgementInjury, poisoning and procedural complications | 1/160 | 0/158 |
| Event | Placebo | Tadalafil |
|---|---|---|
| DizzinessNervous system disorders | 8/160 | 10/158 |
| DyspepsiaGastrointestinal disorders | 0/160 | 8/158 |
| DiarrhoeaGastrointestinal disorders | 2/160 | 5/158 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/160 | 4/158 |
| Back painMusculoskeletal and connective tissue disorders | 2/160 | 4/158 |
| NauseaGastrointestinal disorders | 2/160 | 3/158 |
| FatigueGeneral disorders | 1/160 | 3/158 |
| Upper respiratory tract infectionInfections and infestations | 3/160 | 0/158 |
| ColonoscopyInvestigations | 3/160 | 0/158 |
| HeadacheNervous system disorders | 3/160 | 2/158 |
| Age Continuous(years) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Mean | 67.35 ± 9.13 | 67.41 ± 9.11 | 67.38 ± 9.10 |
| Sex: Female, Male(Participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 160 | 158 | 318 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| Hispanic or Latino | 18 | 20 | 38 |
| Not Hispanic or Latino | 142 | 138 | 280 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 14 | 17 | 31 |
| White | 144 | 137 | 281 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | Tadalafil | Total |
|---|---|---|---|
| United States | 157 | 148 | 305 |
| Puerto Rico | 3 | 10 | 13 |
The record gives a start of Mar 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil